1
|
Li P, Xi Y, Zhang Y, Samad A, Lan W, Wu Y, Zhao J, Chen G, Wu C, Xiong Q. GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease. Cells 2024; 13:437. [PMID: 38474401 DOI: 10.3390/cells13050437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 02/23/2024] [Accepted: 02/28/2024] [Indexed: 03/14/2024] Open
Abstract
Fabry disease (FD) is an X-linked recessive inheritance lysosomal storage disorder caused by pathogenic mutations in the GLA gene leading to a deficiency of the enzyme alpha-galactosidase A (α-Gal A). Multiple organ systems are implicated in FD, most notably the kidney, heart, and central nervous system. In our previous study, we identified four GLA mutations from four independent Fabry disease families with kidney disease or neuropathic pain: c.119C>A (p.P40H), c.280T>C (C94R), c.680G>C (p.R227P) and c.801+1G>A (p.L268fsX3). To reveal the molecular mechanism underlying the predisposition to Fabry disease caused by GLA mutations, we analyzed the effects of these four GLA mutations on the protein structure of α-galactosidase A using bioinformatics methods. The results showed that these mutations have a significant impact on the internal dynamics and structures of GLA, and all these altered amino acids are close to the enzyme activity center and lead to significantly reduced enzyme activity. Furthermore, these mutations led to the accumulation of autophagosomes and impairment of autophagy in the cells, which may in turn negatively regulate autophagy by slightly increasing the phosphorylation of mTOR. Moreover, the overexpression of these GLA mutants promoted the expression of lysosome-associated membrane protein 2 (LAMP2), resulting in an increased number of lysosomes. Our study reveals the pathogenesis of these four GLA mutations in FD and provides a scientific foundation for accurate diagnosis and precise medical intervention for FD.
Collapse
Affiliation(s)
- Ping Li
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Yuqian Xi
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Yanping Zhang
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Abdus Samad
- Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan
| | - Wenli Lan
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Ya Wu
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Jiayu Zhao
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Guangxin Chen
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Changxin Wu
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| | - Qiuhong Xiong
- Institutes of Biomedical Sciences, The Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education of China, The Key Laboratory of Medical Molecular Cell Biology of Shanxi Province, Shanxi University, Taiyuan 030006, China
| |
Collapse
|
2
|
Kume S, Yasuda-Yamahara M, Imamura-Uehara Y, Kuwagata S, Yamahara K, Takeda N, Chin-Kanasaki M, Kato K, Ohno S, Nakagawa Y, Maegawa H. Improvement in Decline Rate of Estimated Glomerular Filtration Rate after Febuxostat Treatment in a Fabry Disease Patient with Enzyme Replacement Therapy-resistant Proteinuria. Intern Med 2022; 61:3077-3081. [PMID: 35283375 PMCID: PMC9646352 DOI: 10.2169/internalmedicine.8993-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Fabry disease is an inherited lysosomal disorder caused by mutations in the alpha-galactosidase A gene. We herein report a Fabry disease patient with enzyme replacement therapy (ERT)-resistant proteinuria who showed improvement in the estimated glomerular filtration rate (eGFR) decline rate after uric acid (UA)-lowering therapy. The patient was diagnosed with Fabry disease at 36 years old. After that, even under ERT, proteinuria and eGFR decline persisted. During the clinical course, serum UA levels were elevated with increases in renal tubular damage markers. Febuxostat administration immediately improved tubular damage and prevented further eGFR decline. UA-mediated tubulopathy may become an additional therapeutic target for eGFR decline in Fabry disease.
Collapse
Affiliation(s)
- Shinji Kume
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Mako Yasuda-Yamahara
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Yoshimi Imamura-Uehara
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Shogo Kuwagata
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Kosuke Yamahara
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Naoko Takeda
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Masami Chin-Kanasaki
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| | - Koichi Kato
- Division of Cardiovascular Medicine, Department of Medicine, Shiga University of Medical Science, Japan
| | - Seiko Ohno
- Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Japan
| | - Yoshihisa Nakagawa
- Division of Cardiovascular Medicine, Department of Medicine, Shiga University of Medical Science, Japan
| | - Hiroshi Maegawa
- Division of Diabetes, Endocrinology & Nephrology, Department of Medicine, Shiga University of Medical Science, Japan
| |
Collapse
|